Physician profile
Robert V Coleman
NPI 1487663928
$1,073.08
in general payments reported to CMS, 2019-2025
12 companies · $167 in 2025
The $167 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $24.67 · 2022: $183 · 2024: $333 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $500.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $247.94 | 2019-2022 | |
| Novo Nordisk INC | $219.79 | 2019-2025 | Ozempic, Rybelsus |
| Corcept Therapeutics | $115.00 | 2025 | Korlym |
| Aadi Bioscience, INC. | $89.00 | 2024 | Fyarro |
| Tandem Diabetes Care, INC. | $87.08 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $72.80 | 2020-2024 | Omnipod |
| Shire North American Group INC | $70.88 | 2019 | |
| Amgen INC. | $64.27 | 2019-2024 | Tepezza |
| Lilly USA, LLC | $35.37 | 2024 | Jardiance |
| Abbvie INC. | $30.80 | 2024 | |
| Beta Bionics, INC. | $24.46 | 2024 | Ilet Bionic Pancreas |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.69 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.